3-(furan-2-yl)-1H-1,2,4-triazol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-(furan-2-yl)-1H-1,2,4-triazol
• 英文别名: 3-(2-Furyl)-1H-1,2,4-triazole；5-(furan-2-yl)-1H-1,2,4-triazole
• 化学式: C₆H₅N₃O
• mdl: MFCD20502733
• 分子量: 135.125
• InChiKey: DRECSUVFISSLIO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(furan-2-yl)-1H-1,2,4-triazol 、 在 potassium carbonate 作用下， 以 水 为溶剂， 以43 %的产率得到(4-((3-(furan-2-yl)-1H-1,2,4-triazol-1-yl)sulfonyl)phenyl)(4-(2-methoxyphenyl)piperazin-1-yl)methanone
  参考文献：
  名称：

  [EN] SULFONYL-TRIAZOLE COMPOUNDS USEFUL AS LIGANDS AND INHIBITORS OF PROSTAGLANDIN REDUCTASE 2
  [FR] COMPOSÉS SULFONYL-TRIAZOLE UTILES EN TANT QUE LIGANDS ET INHIBITEURS DE LA PROSTAGLANDINE RÉDUCTASE 2

  摘要：

  Sulfonyl-triazole compounds and related sulfonyl-heterocycle compounds are described. Exemplary compounds can form covalent adducts with reactive nucleophilic amino acid residues in proteins, such as reactive tyrosines, to form modified proteins and/or to alter the biological activity of the proteins. Pharmaceutical compositions comprising the compounds and methods of inhibiting prostaglandin reductase 2 (PTGR2) are also described. In addition, methods are described for screening proteins to identify druggable amino acid residues, e.g., druggable tyrosine and/or lysine residues.

  公开号：

  WO2022221451A2

文献信息

• Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
  申请人：Edwards Louise

  公开号：US20050272779A1

  公开（公告）日：2005-12-08

  The present invention relates to new compounds of formula I, to pharmaceutical formulations containing the compounds, and to the use of the compounds in the prevention and/or treatment of mGluR5 receptor-mediated disorders.

  本发明涉及公式I的新化合物，包含该化合物的药物配方，以及利用该化合物预防和/或治疗mGluR5受体介导的疾病的用途。
• Compounds
  申请人：Arora Jalaj

  公开号：US20060122397A1

  公开（公告）日：2006-06-08

  The present invention relates to new compounds of formula I, a process for their preparation and new intermediates prepared therein, pharmaceutical formulations containing said compounds and to the use of said compounds in therapy.

  本发明涉及化合物I的新化合物，其制备过程和其中制备的新中间体，含有该化合物的制药配方以及在治疗中使用该化合物的用途。
• ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS
  申请人：Edwards Louise

  公开号：US20080045571A1

  公开（公告）日：2008-02-21

  The present invention relates to new compounds of formula I, to pharmaceutical formulations containing the compounds, and to the use of the compounds in the prevention and/or treatment of mGluR5 receptor-mediated disorders.

  本发明涉及公式I的新化合物，包括含有该化合物的制药配方，以及该化合物在预防和/或治疗mGluR5受体介导的疾病中的使用。
• COMPOUND CAPABLE OF INHIBITING 11-BETA HYDROXYSTERIOD DEHYDROGENASE
  申请人：Vicker Nigel

  公开号：US20110112151A1

  公开（公告）日：2011-05-12

  There is provided a compound of formula R 1 —CO—X—Y—Z—R 2 wherein X and Z are each optional groups that are, independently, saturated or unsaturated carbon chains having a length of 1 to 3 carbons; Y is SO, S, SO 2 , CH═CH, CH 2 CH 2 or O; R 1 is wherein denotes the point of attachment; R 2 is a heteroaryl group comprising an optionally substituted 5 or 6 membered ring, which ring contains only carbon and at least one nitrogen, or contains only carbon, and at least two nitrogens and at least one sulfur; and wherein (i) when R 1 is and —CO—X—Y—Z— is CO—CH 2 —SO, CO—CH 2 —S, or CO—CH 2 —SO 2 , R 2 is other than and; (ii) when R 1 is and —CO—X—Y—Z— is —CO—CH 2 —O—, R 2 is other than

  提供了一个化合物的公式R1—CO—X—Y—Z—R2，其中X和Z是可选的基团，它们分别是具有1至3个碳原子的饱和或不饱和碳链；Y是SO、S、SO2、CH═CH、 或O；R1是其中的连接点；R2是一个杂环基团，包括一个可选取代的5或6元环，该环仅包含碳和至少一个氮，或仅包含碳、至少两个氮和至少一个硫；其中(i)当R1是且—CO—X—Y—Z—为CO—CH2—SO、CO— —S或CO— —SO2时，R2不是和；(ii)当R1是且—CO—X—Y—Z—为—CO— —O—时，R2不是。
• 7-Oxo-4-thia-1-azabicyclo(3.2.0)hept-2-ene derivatives
  申请人：HOECHST UK LIMITED

  公开号：EP0127847A1

  公开（公告）日：1984-12-12

  A process for the preparation of a compound of the general formula I is described according to which a compound of the general formula IIb is reacted with a compound of formula III in which L represents a leaving group, generally carrying out the reaction in the presence of a base. R' represents an alkylene, alkenylene or alkynylene group, having from 1 to 4 carbon atoms, and R2 represents a heterocyclic group having a five-membered or 6-membered ring with 1 to 4 heteroatoms, selected from oxygen sulfur and nitrogen, and being linked to the adjacent sulphur atom via a ring carbon atom.

  通式 I 化合物的制备工艺 的制备方法，根据该方法，通式 IIb 的化合物 与通式 III 的化合物反应 其中 L 代表离去基团，通常在碱存在下进行反应。 R' 代表具有 1 至 4 个碳原子的亚烷基、亚烯基或亚炔基，以及 R2 代表杂环基团，具有 1 至 4 个杂质原子的五元环或六元环，这些杂质原子可选 自氧、硫和氮，并通过环上的碳原子与相邻的硫原子相连。